These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36805596)

  • 21. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
    Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
    Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATRX/DAXX: Guarding the Genome against the Hazards of ALT.
    Clatterbuck Soper SF; Meltzer PS
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomere sequence content can be used to determine ALT activity in tumours.
    Lee M; Teber ET; Holmes O; Nones K; Patch AM; Dagg RA; Lau LMS; Lee JH; Napier CE; Arthur JW; Grimmond SM; Hayward NK; Johansson PA; Mann GJ; Scolyer RA; Wilmott JS; Reddel RR; Pearson JV; Waddell N; Pickett HA
    Nucleic Acids Res; 2018 Jun; 46(10):4903-4918. PubMed ID: 29718321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer.
    Mori JO; Keegan J; Flynn RL; Heaphy CM
    J Clin Pathol; 2024 Jan; 77(2):82-86. PubMed ID: 37890990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
    Clynes D; Jelinska C; Xella B; Ayyub H; Scott C; Mitson M; Taylor S; Higgs DR; Gibbons RJ
    Nat Commun; 2015 Jul; 6():7538. PubMed ID: 26143912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.
    Hu Y; Shi G; Zhang L; Li F; Jiang Y; Jiang S; Ma W; Zhao Y; Songyang Z; Huang J
    Sci Rep; 2016 Aug; 6():32280. PubMed ID: 27578458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative lengthening of telomeres in cancer stem cells in vivo.
    Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
    Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
    Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
    Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative Lengthening of Telomeres: DNA Repair Pathways Converge.
    Sobinoff AP; Pickett HA
    Trends Genet; 2017 Dec; 33(12):921-932. PubMed ID: 28969871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
    Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
    Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas.
    Udugama M; Hii L; Garvie A; Cervini M; Vinod B; Chan FL; Das PP; Mann JR; Collas P; Voon HPJ; Wong LH
    Nat Commun; 2021 May; 12(1):2584. PubMed ID: 33972520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination in ALT Cancer Cells.
    Ramamoorthy M; Smith S
    Cancer Cell; 2015 Sep; 28(3):357-69. PubMed ID: 26373281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
    de Nonneville A; Salas S; Bertucci F; Sobinoff AP; Adélaïde J; Guille A; Finetti P; Noble JR; Churikov D; Chaffanet M; Lavit E; Pickett HA; Bouvier C; Birnbaum D; Reddel RR; Géli V
    EMBO Mol Med; 2022 Oct; 14(10):e15859. PubMed ID: 35920001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A unified alternative telomere-lengthening pathway in yeast survivor cells.
    Kockler ZW; Comeron JM; Malkova A
    Mol Cell; 2021 Apr; 81(8):1816-1829.e5. PubMed ID: 33639094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
    Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
    Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
    Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
    Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.
    Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M;
    Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.
    Hartlieb SA; Sieverling L; Nadler-Holly M; Ziehm M; Toprak UH; Herrmann C; Ishaque N; Okonechnikov K; Gartlgruber M; Park YG; Wecht EM; Savelyeva L; Henrich KO; Rosswog C; Fischer M; Hero B; Jones DTW; Pfaff E; Witt O; Pfister SM; Volckmann R; Koster J; Kiesel K; Rippe K; Taschner-Mandl S; Ambros P; Brors B; Selbach M; Feuerbach L; Westermann F
    Nat Commun; 2021 Feb; 12(1):1269. PubMed ID: 33627664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance.
    Li F; Wang Y; Hwang I; Jang JY; Xu L; Deng Z; Yu EY; Cai Y; Wu C; Han Z; Huang YH; Huang X; Zhang L; Yao J; Lue NF; Lieberman PM; Ying H; Paik J; Zheng H
    Nat Commun; 2023 Mar; 14(1):1756. PubMed ID: 36991019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression.
    Gocha ARS; Harris J; Groden J
    Mutat Res; 2013; 743-744():142-150. PubMed ID: 23219603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.